Bold claim: Early shifts in blood lipids may reveal new doors to diagnosing and treating primary biliary cholangitis (PBC).
A recent study from multiple Polish medical centers examined the plasma sphingolipid profiles of 45 patients with early-stage PBC who were receiving standard ursodeoxycholic acid therapy, comparing them to 30 healthy controls. Using cutting-edge ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS), researchers identified a distinct pattern of sphingolipid disruptions that appear linked to inflammation, immune imbalance, and early liver fibrosis.
Key findings on sphingolipids and PBC
- A prominent overall decline in total sphingolipids was observed in the PBC group, with marked reductions in phosphorylated lipids such as sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (SPA1P). These molecules are known regulators of immune responses and vascular function. The reductions aligned with portal hemodynamic abnormalities detected by Doppler ultrasound, suggesting a possible connection to the circulatory disturbances often seen in cholestatic liver disease.
- Conversely, levels of C18:1-ceramide were elevated in individuals with PBC. This ceramide subtype tended to associate with increased liver stiffness, a sign of advancing fibrosis. In contrast, very-long-chain ceramides, which can have protective metabolic roles, were reduced.
Links between lipids and inflammation emerge
The study also found several notable associations between lipid changes and inflammatory markers. Specifically, sphingosine levels correlated positively with interleukin-6, a cytokine implicated in chronic inflammation and autoimmune processes. These relationships support the view that sphingolipids are active participants in the immune dysregulation and tissue remodeling that drive PBC, not merely bystanders.
Implications and future directions
The authors conclude that early PBC may feature a selective, disease-specific sphingolipid alteration pattern. While more research is needed to confirm these observations, the data raise the possibility that certain sphingolipids could serve as biomarkers of disease activity or even as targets for therapy, offering a fresh angle on the management of cholestatic liver diseases.
Reference
Rogalska M et al. Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation. Sci Rep. 2025; 15:42502.
Author note: This content is provided under the Creative Commons Attribution-Non Commercial 4.0 License.
